Neforex

Quick links to important sections

Neforex

Method of action: Pain Reliever

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neforex

Property Description
Active Ingredient Nefopam hydrochloride
Forms Solution for injection, Oral tablet
Pharmacological Class Centrally Acting Analgesic, Non-Opioid
General Purpose Relief of moderate to severe pain
Origin Synthetic benzoxazocine derivative

What is Neforex and How is it Classified?

Neforex is the trade name for a potent medication whose active substance is Nefopam, specifically formulated as Nefopam hydrochloride. It is classified as a powerful centrally acting analgesic, meaning its pain-relieving effects are processed in the brain and spinal cord, not primarily at the local site of trauma. This compound is a synthetic drug that belongs to the unique benzoxazocine derivative chemical class. Nefopam acts by inhibiting the reuptake of monoamines in the central nervous system, which characterizes it as a distinct non-opioid and non-narcotic pain reliever. This action is clinically recognized for providing effective pain relief without relying on the typical opioid receptor mechanisms.

Composition and Available Pharmaceutical Forms

The core composition of Neforex consists of the single active ingredient Nefopam hydrochloride. This substance is provided in two principal dosage forms to suit different patient needs: a solution for injection and an oral tablet. The injectable form is typically an aqueous solution intended for delivery via the intravenous or intramuscular routes, while the tablet is designed for assimilation through the oral route. The availability of both quick-acting injectable forms and convenient oral forms is a differentiating feature, allowing for flexible management of pain across varying intensity levels and settings.

General Therapeutic Purpose of Nefopam

The general purpose of this medication is to provide robust relief for moderate to severe pain. It achieves this by focusing on antinociception, the central disruption of pain signaling. Nefopam is often utilized as an effective pain reliever in post-operative care or for managing complex chronic syndromes. Because its mechanism is distinct from conventional analgesics, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Nefopam serves as a valuable alternative or addition to treatment regimens. The medication has a defined role in acute pain management due to its unique centrally mediated analgesic effect.

What side effects are possible with Neforex?

Possible Side Effects and Safety Information

The safety profile of Neforex (Nefopam) is officially documented by health authorities, classifying adverse reactions according to their frequency and the body system affected. These regulatory classifications provide a neutral description of possible experiences without offering medical advice or instructions.

Frequency-Classified Adverse Reactions

The most frequently reported effects are generally related to the Central Nervous System (CNS) and anticholinergic activity:

  • Very Common (Affects more than 1 in 10 people): Dry mouth and sweating (hyperhidrosis).
  • Common (Affects 1 to 10 in 100 people): Nausea, dizziness, headache, drowsiness, tremor, tachycardia (fast heart rate), palpitations, hypotension, and urinary retention.
  • Uncommon to Rare: Less frequent effects include confusion, hallucinations, and allergic reactions. Some individuals may experience a temporary, harmless pink discolouration of the urine.

Serious Adverse Reactions and Safety Constraints

Official labeling identifies certain serious reactions, including convulsions (seizures) and anaphylactic shock (severe allergic reaction). Safety constraints apply to specific conditions and patient groups, as defined in regulatory documents:

  • Population-Specific Notes: Older adults may be more susceptible to CNS effects, such as confusion. Use is not established or recommended for the paediatric population (under 12 or 15 years, depending on the regulatory region).
  • Restrictions: The drug is officially restricted in individuals with a history of convulsive disorders or epilepsy. It should not be given to patients currently taking Monoamine Oxidase Inhibitors (MAOIs), nor is it recommended for the management of myocardial infarction.
  • Exposure Pattern: Cases of dependence and abuse have been reported with long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Neforex (Nefopam hydrochloride) overdose is defined by severe toxicity primarily affecting the neurological and cardiovascular systems, requiring immediate emergency response.

Domain Official Regulatory Statement
Documented Manifestations Clinical signs include convulsions (seizures), coma, hallucinations, agitation, tachycardia (rapid heartbeat), and hyperdynamic circulation.
Required Action Immediate medical attention or emergency treatment in a hospital is required for suspected overdose or the onset of severe symptoms.

Overdose presents a serious syndrome with the potential for life-threatening outcomes. Regulator-mandated management involves cardiac and respiratory monitoring in hospital as part of routine supportive measures. No specific antidote is documented; therefore, treatment is symptomatic and supportive. Procedures include prompt drug removal using gastric lavage or activated charcoal, and controlling severe symptoms like convulsions with diazepam or cardiovascular effects with beta-adrenergic blockers. Older patients are noted to be more susceptible to CNS side effects, such as confusion and hallucinations, which are relevant considerations in overdose presentation.

Therapeutic Uses of Neforex

Neforex is an analgesic commonly used to help with symptoms related to physical discomfort across various clinical settings. It is generally applied in scenarios where additional management of discomfort is required, offering supportive relief when common non-opioid pain medications are insufficient for adequate easing of symptoms. The medication is used in situations where other common non-opioid pain medications are insufficient for relief, covering moderate pain, discomfort after an operation, serious injury, and long-term conditions.


The primary use of Neforex is often in managing symptoms that are intense or disruptive, such as those encountered following surgical procedures or acute medical events. The medication is relevant in contexts marked by increased discomfort and can be utilized in multimodal pain management strategies. This provides supportive benefit by contributing to a lower overall need for narcotic pain medications, which contributes to patient comfort and supports general well-being during symptomatic periods. It is also applied in managing conditions involving episodic or fluctuating manifestations, including some forms of musculo-skeletal and chronic pain, assisting with maintaining functional stability.

“Neforex is applied when symptoms create noticeable physiological strain and require supportive relief.”


Quick Fact: Relief for Moderate to Severe Pain

Eligibility and Restrictions for Use

Eligibility for Neforex Use: Official Regulatory Information

Official regulatory documents define strict population eligibility for Neforex (Nefopam), classifying individuals into three main categories: allowed, not recommended, and strictly contraindicated.

Category Official Regulatory Statement
Populations for whom use is allowed Most adults (generally defined as 18 years and over).
Populations for whom use is contraindicated Patients with a history of convulsive disorders or epilepsy. Patients taking Monoamine Oxidase Inhibitors (MAOIs). Known hypersensitivity to the active substance or excipients. For pain caused by myocardial infarction (heart attack).

Age and Physiological Restrictions

Neforex is not recommended for children under 12 years of age, as safety and efficacy have not yet been established for the pediatric population. Older adults may require special consideration due to increased susceptibility to central nervous system effects.

Regarding reproductive status, use during pregnancy is not recommended unless considered absolutely essential. Breastfeeding should be discontinued during treatment, as the drug is known to be excreted in human milk.

Condition-Specific Limitations

Caution is advised for patients with hepatic or renal insufficiency due to potential interference with drug metabolism and excretion. The medicine should also be used with caution in those at risk of urinary retention or with certain types of glaucoma (angle-closure).


Connection to the overall eligibility profile: Official regulatory documents establish absolute prohibitions, or contraindications, for patients with specific neurological or cardiac histories, as well as those on particular concurrent medications (MAOIs). Separately, official restrictions mandate caution for patients with organ dysfunction and define specific age-based exclusions, ensuring the medicine is used only by populations deemed eligible by governing authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Neforex (Nefopam) is strictly defined by formal prohibitions and risks of additive pharmacodynamic effects. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, a restriction that remains in place for 14 days after the MAOI is discontinued. This prohibition is due to the documented risk of severe hypertensive or serotonergic crises.

The interaction profile is largely structured by the risk of additive effects with multiple drug classes that act on the central or autonomic nervous systems. Caution is officially advised when Neforex is co-administered with Central Nervous System (CNS) depressants, including opioid analgesics, benzodiazepines, and sedative H1 antihistamines. These combinations may result in an enhanced central effect. Similarly, additive effects are documented with other anticholinergic and sympathomimetic agents, such as tricyclic antidepressants.

A unique procedural constraint is noted: Neforex may interfere with certain screening tests for both benzodiazepines and opioids, which can yield false positive results.

The drug's metabolism and excretion are affected by specific patient populations. Hepatic and renal insufficiency interfere with clearance, and patients with end stage renal disease are officially noted to be susceptible to increased serum peak concentrations, heightening the overall interaction risk in this group.

Mechanism of Action

How Neforex Works

The pharmacological action of Nefopam is multimodal and confined to the central nervous system (CNS), operating via two simultaneous mechanistic domains.

Enhancement of Descending Pain Control

The initial mechanism involves the simultaneous inhibition of the Serotonin Transporter (SERT), Norepinephrine Transporter (NET), and Dopamine Transporter (DAT) in the brain and spinal cord. This action elevates the synaptic concentration of these key monoamines, which increases the activity of the Descending Pain Modulatory System (DPMS). This enhancement of inhibitory pathways attenuates the flow of nociceptive signals.

Central Stabilization of Neuronal Excitability

The second domain involves a direct, non-receptor-mediated action on neuronal membranes by blocking Voltage-Gated Sodium and Calcium Channels. This physical interaction increases the resting membrane potential of central neurons, decreasing their overall excitability and attenuating the process of central sensitization. This mechanism attenuates the excessive transmission of signals, including those involved in nociceptive signal amplification. Additionally, it modulates the central thermoregulatory centers.

Dosage and Administration Information

How to Use Neforex

Neforex (Nefopam hydrochloride) is available in two principal delivery methods, defining its administration routes: an oral tablet for ingestion and a solution for injection suitable for deep intramuscular (IM) or slow intravenous (IV) administration.

Dosage and Frequency Patterns

The standard oral dosage for adults is typically 30 mg to 60 mg, taken three times daily (TID). The maximum recommended oral dose is 270 mg per day, or 90 mg taken TID. The oral tablets can be consumed with or without food. In the event of a missed dose, the protocol is to take the next scheduled dose at the usual time and not take a double dose.

For parenteral use, a single dose is generally 20 mg. The IM route may be repeated every 6 hours, while the IV route allows repetition every 4 hours, respecting the maximum daily limit of 120 mg for the injection form.

Procedural and Population-Specific Rules

Intravenous administration involves specific procedural care: the injection is delivered as a slow infusion over a period of more than 15 minutes, often requiring prior dilution with a standard perfusion fluid such as isotonic sodium chloride. Standard use includes dose adjustments for certain groups. For older adults, the starting oral dose is reduced, generally not exceeding 30 mg TID. Additionally, a dose reduction is applied for patients with terminal renal insufficiency to manage serum concentration risk. The medication is not recommended for children under 12 years of age.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Neforex

Evidence for Use in Acute Pain Management (Postoperative Settings)

Clinical research examining Neforex has focused extensively on its use for outcomes related to physical discomfort experienced in the short-term period following surgical procedures. The majority of this evidence comes from Randomized Controlled Trials (RCTs), which are commonly used designs for clinical evaluation. These studies monitored adult patients recovering from various operations. Research examined patient-reported outcomes describing perceived discomfort and also tracked the use of other pain medications, particularly opioids, during the study period.

Studies examined and reported patterns related to the total amount of opioids needed by patients. This pattern contributes to the broader evidence landscape related to opioid consumption in post-operative care. In research contexts where Neforex was evaluated alongside other non-opioid medications, reported measurements of pain intensity showed variability across trials and surgical types. There is limited information for long-term outcomes related to pain or functional recovery after discharge.


Evidence for Use in Chronic and Specific Discomforts

Research has examined Neforex in contexts relevant to conditions involving periods of heightened symptoms, such as chronic pain, particularly in older trials focusing on conditions like rheumatoid arthritis. The evidence base here consists mainly of older, smaller studies.

Neforex was also evaluated in studies examining specific physical symptoms. Research explored its use in patients experiencing post-operative shivering after surgery and in patients dealing with Catheter-Related Bladder Discomfort (CRBD). Data from multiple studies and meta-analyses monitored the incidence and severity of shivering. Similarly, for CRBD, studies monitored short-term changes in symptom severity, although subgroup findings are uncertain and specific to patients with indwelling catheters. Comparative evidence is lacking for many chronic pain scenarios.


What Remains Uncertain About the Research for Neforex

The available research provides valuable insight into short-term changes. A key uncertainty is the variability across studies in research that compared Neforex to non-opioid medications. For long-term use, the core limitation is the absence of dedicated, large-scale clinical trials. Research for some indications includes older trials where sample sizes were modest and evidence quality varies across studies.

Key Studies & References

  1. Nefopam 30mg film-coated tablets - Summary of Product Characteristics (Regulatory Document on Indications and Safety)

Frequently Asked Questions (FAQ)

Common questions about Neforex (FAQ)


Q: What happens if I miss a day of Neforex?

If a dose is missed, official instructions advise taking it as soon as it is remembered, unless it is nearly time for your next scheduled dose. Regulatory information consistently notes that taking two doses at once to make up for a missed one is not recommended.


Q: Does Neforex interact with common over-the-counter pain relievers?

Official product information indicates that Neforex may be co-administered with common non-opioid pain relievers, such as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, official documents advise caution when combining Neforex with stronger pain medication, especially those that act on the central nervous system.


Q: Can Neforex be taken if I have a history of liver issues?

Official regulatory warnings advise caution for patients with liver (hepatic) or kidney (renal) insufficiency. This is due to the potential for the drug to accumulate in the body, which increases the risk of side effects. For these specific groups, the product label notes that a dosage adjustment may be necessary.


Q: Is it true that Neforex can cause weight changes?

Official safety documents categorize reported adverse reactions by frequency. Changes in weight (gain or loss) are not categorized among the officially reported adverse reactions in the standard frequency tables for this medication.


Q: Are there any known interactions between Neforex and alcohol?

Official warnings advise against the co-administration of alcohol during treatment with Neforex. Regulatory documents state that alcohol consumption can increase the sedative effect of Neforex, which could impair a person's ability to drive or use machinery safely.


Q: Can Neforex affect sleep patterns?

Yes, Neforex can affect sleep patterns. Drowsiness is listed as a common reported effect in regulatory documents. Less frequently, official documents also report insomnia, or trouble sleeping, as an undesirable effect.


Q: How do I know if the side effects I am experiencing are common for Neforex?

Official documents classify side effects into frequency categories, such as 'Very Common' (affecting more than 1 in 10 people) or 'Common' (affecting 1 to 10 in 100 people). You can reference the specific symptoms you are experiencing against these official frequency classifications found in the patient information leaflet.


Q: What is the experience of people who have been on Neforex for several years?

Official clinical research has focused extensively on short-term use, and dedicated, large-scale long-term trials providing outcome data are absent. Warnings exist that long-term use has been associated with reports of dependence and abuse. If discontinuing after an extended period, a gradual reduction in dosage is described as a recommended measure.


Q: Is Neforex considered a preventative medicine?

The general purpose of Neforex, as stated in official documents, is for the relief of moderate to severe pain. It is generally not classified for widespread, long-term preventative use, although evidence indicates it has been studied in specific acute clinical scenarios, such as preventing post-operative shivering.


Q: How quickly does Neforex typically start to work for most people?

According to official pharmacokinetic data, for the oral tablet form, the onset of pain relief is generally reported to occur within 30 to 45 minutes of ingestion. For the injectable solution, the effects are generally more rapid.


Q: Are there any specific foods or drinks that should be avoided when taking Neforex?

Official product information states the oral tablet can be taken with or without food. There are no known restrictions on specific foods, but co-administration with alcohol is an officially noted prohibition due to the known risk of increased sedative effects.


Q: How long after stopping Neforex does it stay in your system?

The terminal elimination half-life of Neforex is typically between 3 and 8 hours. Its active metabolite, desmethylnefopam, has a longer half-life, generally reported as 10 to 15 hours. The drug and its metabolite are mainly eliminated from the body via the urine.


Q: Why is it important to continue taking Neforex even if I feel better?

The duration of treatment is determined by the authorized prescriber. Official guidance emphasizes consulting a healthcare professional before making any changes to treatment, especially after long-term use, as the dose may need to be reduced gradually to avoid potential withdrawal symptoms.


Q: Does Neforex have a bitter taste if dissolved?

The oral tablet is designed to be swallowed whole with water. Official instructions advise against chewing, crushing, or breaking the tablet, and information regarding the taste if dissolved or crushed is not provided in regulatory documents.


Q: Can Neforex affect fertility?

Official safety documents state that whether Neforex affects fertility in humans is currently unknown. Regulatory information indicates that data suggesting a reduction in human fertility is not available.


Q: Is there a maximum time someone can take Neforex according to the manufacturer?

Regulatory documents do not define a fixed, absolute maximum duration for use. However, general official guidance suggests using the lowest effective dose for the shortest time necessary to control symptoms.


Q: Are there any known drug-disease interactions with Neforex?

Official documents list specific conditions that require caution or prohibit use. These include strict contraindications for patients with a history of convulsive disorders/epilepsy and for pain related to myocardial infarction. Caution is also advised for patients with liver or kidney insufficiency, risk of urinary retention, and certain types of glaucoma.


Q: Can Neforex make my skin more sensitive to the sun?

Official safety documents categorize reported side effects by frequency. Increased sensitivity to the sun (photosensitivity) is not included in the officially categorized lists of reported side effects.


Q: What is the typical time frame to see the full benefits of Neforex?

While the initial onset of pain relief is generally seen within 30 to 45 minutes for the oral form, the full therapeutic effect can vary. No single time frame for achieving 'full benefits' is universally defined across all official documents, as this depends on the individual patient and the pain condition being managed.


Q: Does Neforex have different uses in other countries?

Neforex is officially approved in many countries, including those in Europe, with the general therapeutic purpose defined as the relief of moderate to severe pain. The core approved indications and overall classification are consistent across major international regulatory bodies.

How should Neforex be stored and disposed of?

How to Store and Dispose of Neforex?

The storage and disposal of Neforex (nefopam hydrochloride) are strictly defined by regulatory guidelines to ensure product integrity and safety.

Storage Requirements

  • Temperature and Protection: Neforex must be stored below 30 C and must not be frozen. It must be protected from light and moisture and kept in its original outer carton.
  • Child Safety: The medication must be stored out of the sight and reach of children.
  • Stability Constraint: The diluted solution for injection must be used immediately. If not used right away, it can be stored between 2 C and 8 C and used within 24 hours.

Disposal Instructions

  • Unused or expired Neforex must be disposed of in accordance with local regulations and pharmaceutical waste procedures.
  • The product must not be allowed to enter sewers or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neforex found in:

A-Z Index: